Key Points
- Relmada Therapeutics CFO Maged Shenouda bought 79,800 shares at an average price of $4.25, investing $339,150 and increasing his direct ownership by 8.67% to 1 million shares.
- Shenouda also purchased 120,200 shares for $504,840 the previous day, bringing his two-day insider buying to nearly $844,000.
- Analysts maintain a “Moderate Buy” consensus with a $12.00 average price target, while RLMD recently traded at $4.52 and reported a quarterly loss of $0.11 per share, better than estimates.
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda purchased 79,800 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were purchased at an average cost of $4.25 per share, for a total transaction of $339,150.00. Following the purchase, the chief financial officer directly owned 1,000,000 shares in the company, valued at $4,250,000. This trade represents a 8.67% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Maged Shenouda also recently made the following trade(s):
- On Wednesday, September 9th, Maged Shenouda acquired 120,200 shares of Relmada Therapeutics stock. The stock was purchased at an average price of $4.20 per share, for a total transaction of $504,840.00.
Relmada Therapeutics Price Performance
NASDAQ:RLMD opened at $4.52 on Friday. The firm has a 50-day moving average of $5.06 and a two-hundred day moving average of $6.04. The stock has a market cap of $482.15 million, a P/E ratio of -5.02 and a beta of 0.45. Relmada Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $8.00.
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.09. As a group, equities analysts expect that Relmada Therapeutics, Inc. will post -0.6 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Relmada Therapeutics in a research note on Thursday, June 18th. HC Wainwright assumed coverage on Relmada Therapeutics in a research report on Thursday, June 18th. They issued a "buy" rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Relmada Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $12.00.
Get Our Latest Stock Analysis on Relmada Therapeutics
Institutional Investors Weigh In On Relmada Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in shares of Relmada Therapeutics in the 2nd quarter valued at about $28,000. LMR Partners LLP bought a new position in shares of Relmada Therapeutics during the second quarter worth about $33,000. Goldman Sachs Group Inc. acquired a new position in Relmada Therapeutics in the first quarter worth about $33,000. California State Teachers Retirement System acquired a new position in Relmada Therapeutics in the second quarter worth about $62,000. Finally, Legal & General Group Plc bought a new stake in Relmada Therapeutics in the second quarter valued at about $64,000. Institutional investors own 45.24% of the company's stock.
Relmada Therapeutics Company Profile
(
Get Free Report)
Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada's research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.
Relmada's lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
